The Role of Statins in Preventing Contrast-Induced Acute Kidney Injury: A Narrative Review

Angiology

Volumn 66, Issue 8, 2015, Pages 701-707

  Akyuz, Sukru ^a   Yaylak, Baris ^b   Altay, Servet ^a   Kasikcioglu, Hulya ^a   Cam, Nese ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Diyarbakir Training and Research Hospital   (Turkey)

Author keywords

acute kidney injury; angiography; contrast media; statins

Indexed keywords

C REACTIVE PROTEIN; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ASSAY; CONTRAST INDUCED ACUTE KIDNEY INJURY; CONTRAST INDUCED NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; NEUTROPHIL LYMPHOCYTE RATIO; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SECONDARY PREVENTION; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DIAGNOSTIC USE; DOSE RESPONSE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84939478089     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714549556     Document Type: Review

References (56)

1. Chen SL, Zhang J, Yei F,. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008; 126 (3): 407-413.
2. Katzberg RW, Haller C,. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl. 2006;(100): S3-S7.
3. Ichiki T, Takeda K, Tokunou T,. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001; 21 (12): 1896-1901.
4. Bonetti PO, Lerman LO, Napoli C, Lerman A,. Statin effects beyond lipid lowering-are they clinically relevant. Eur Heart J. 2003; 24 (3): 225-248.
5. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J,. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998; 101 (12): 2711-2719.
6. Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK,. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev. 2012; 2012: 831748.
7. Davignon J,. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109 (23 suppl 1): III39-III43.
8. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME,. Statins and contrast-induced acute kidney injury with coronary angiography: systematic review and meta-analysis [published online May 19, 2014]. Am J Med. 2014.
9. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G,. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials [published online April 6, 2014]. J Thromb Thrombolysis. 2014.
10. Li Y, Liu Y, Fu L, Mei C, Dai B,. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One. 2012; 7 (4): e34450.
11. Jo SH, Koo BK, Park JS,. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J. 2008; 155 (3):499. e1-e8.
12. Toso A, Maioli M, Leoncini M,. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010; 105 (3): 288-292.
13. Ozhan H, Erden I, Ordu S,. Efficacy of short term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010; 61 (7): 711-714.
14. Patti G, Ricottini E, Nusca A,. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Contrast-Induced Nephropathy] trial). Am J Cardiol. 2011; 108 (1): 1-7.
15. Acikel S, Muderrisoglu H, Yildirir A,. Prevention of contrast induced impairment of renal function by short term or long term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010; 21 (8): 750-757.
16. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY,. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Zhonghua Xin Xue Guan Bing Za Zhi. 2009; 37 (5): 394-396.
17. Xinwei J, Xianghua F, Jing Z,. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104 (4): 519-524.
18. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F,. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014; 63 (1): 71-79.
19. Han Y, Zhu G, Han L,. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014; 63 (1): 62-70.
20. Li W, Fu X, Wang Y,. Beneficial effects of high dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012; 122 (3): 195-202.
21. Quintavalle C, Fiore D, De Micco F,. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012; 126 (25): 3008-3016.
22. Oliveira MSd, Martins KBA, Costa Jr, Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users. Rev Bras Cardiol Invasiva. 2012; 20 (3): 303-308.
23. Ha SJ, Kim JW, Yoo TK,. Usefulness of statin pretreatment to prevent contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention in real world. Eur Heart J. 2011; 32 (suppl 1): 935-1118.
24. Jo SH, Hahn JY, Lee SY,. High dose atorvastatin pretreatment for preventing contrast-induced nephropathy in patients receiving primary percutaneous coronary intervention: prespecified substudy of a prospective randomized clinical trial. Am J Cardiol. 2013; 111 (7): 95B-96B.
25. Miao Y, Yu-Jie Z,. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011; 97 (suppl 3): A229.
26. OGara PT, Kushner FG, Ascheim DD,. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61 (4): e78-140.
27. Hamm CW, Bassand JP, Agewall S, ESC Committee for Practice Guidelines. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32 (23): 2999-3054.
28. Stone NJ, Robinson J, Lichtenstein AH,. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 (25 suppl 2): S1-S45.
29. Briguori C, Visconti G, Focaccio A,. Novel Approaches for Preventing or Limiting Events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009; 54 (23): 2157-2163.
30. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2 (1): 1-138.
31. Jadad AR, Moore RA, Carroll D,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17 (1): 1-12.
32. Verhagen AP, de Vet HC, de Bie RA,. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998; 51 (12): 1235-1241.
33. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011; 124 (11): 1250-1259.
34. O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR,. The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013; 64 (8): 576-582.
35. Cecere N, Jadoul M, Labriola L,. Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014; 64 (3): 332.
36. Mikhailidis DP, Athyros VG,. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014; 10 (1): 8-9.
37. Newman DJ, Thakkar H, Edwards RG,. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47 (1): 312-318.
38. Dharnidharka VR, Kwon C, Stevens G,. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40 (2): 221-226.
39. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X,. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009; 32 (11): 644-648.
40. Li JJ,. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J. 2005; 118 (21): 1817-1826.
41. Katsuda S, Kaji T,. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003; 10 (5): 267-274.
42. Ge CJ, Lu SZ, Feng LX,. Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion. Chin Med J (Engl). 2012; 25 (14): 2472-2476.
43. Rudnick MR, Berns JS, Cohen RM, Goldfarb S,. Nephrotoxic risks of renal angiography: contrast-media associated nephrotoxicity and atheroembolism. A critical review. Am J Kidney Dis. 1994; 24 (4): 713-727.
44. Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3 (1): 1-150.
45. Akyuz S, Ergelen M, Ergelen R, Uyarel H,. Contrast-induced nephropathy: a contemporary and simplified review. Interv Cardiol. 2010; 2 (2): 233-242.
46. Lucreziotti S, Centola M, Salerno-Uriarte D,. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction. Int J Cardiol. 2014; 174 (1): 37-42.
47. Aurelio A, Durante A,. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014; 128 (1): 62-72.
48. Barbieri L, Verdoia M, Schaffer A,. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study. Angiology. 2015; 66 (4): 333-338.
49. Jian-Wei Z, Yu-Jie Z, Shu-Jun C, Qing Y, Shi-Wei Y, Bin N,. Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology. 2014; 65 (5): 402-407.
50. Borekci A, Gur M, Turkoglu C,. Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2015; 66 (4): 339-345.
51. Ucar H, Gur M, Ylldlrlm A,. Increased aortic stiffness predicts contrast-induced nephropathy in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Angiology. 2014; 65 (9): 806-811.
52. Kurtul A, Yarlioglues M, Murat SN,. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Angiology. 2015; 66 (5): 433-440.
53. Kaya A, Kaya Y, Topcu S,. Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology. 2014; 65 (1): 51-56.
54. Celik O, Ozturk D, Akin F,. Association between contrast media volume-glomerular filtration rate ratio and contrast-induced acute kidney injury after primary percutaneous coronary intervention. Angiology. 2015; 66 (6): 519-524.
55. Fu N, Li X, Yang S,. Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology. 2013; 64 (3): 188-194.
56. Raposeiras-Roubín S, Aguiar-Souto P, Barreiro-Pardal C,. GRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function. Angiology. 2013; 64 (1): 31-39.